Journal
STEM CELLS INTERNATIONAL
Volume 2011, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.4061/2011/235176
Keywords
-
Categories
Funding
- Ohio Department of Development (Center for Stem Cell and Regenerative Medicine Pilot Program)
- NIH [NIAID K08 A57801]
- NIAMS [R01 AR05028]
- Hematopoietic Stem Cell Core Facility of the Case Comprehensive Cancer Center (NCI) [P30 CA43703]
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050208] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Allogeneic hematopoietic stem cell transplantation is the main curative therapy for many hematologic malignancies. Its potential relies on graft-versus-tumor effects which associate with graft-versus-host disease. Mesenchymal stromal cells (MSCs) possess immunomodulatory properties that make them attractive therapeutic alternatives. We evaluated the in vitro immunosuppressive activity of medium conditioned by human MSCs from 5 donors expanded 13 passages with or without FGF-2. FGF-2 supplementation increased expansion 3,500- and 240,000-fold by passages 7 and 13, respectively. There were no differences in immunosuppressive activity between media conditioned by passage-matched cells expanded under different conditions, but media conditioned by FGF-treated MSCs were superior to population doubling-matched controls. The immunosuppressive activity was maintained in three of the preparations but decreased with expansion in two. The proliferation induced by FGF-2 did not result in loss of immunosuppressive activity. However, because the immunosuppressive activity was not consistently preserved, caution must be exercised to ensure that the activity of the cells is sufficient after extensive expansion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available